- Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) received the official minutes from a Type B pre-Investigational New Drug Application (IND) meeting with the FDA.
- The meeting was related to TNX-102 SL1 (cyclobenzaprine HCl sublingual tablets) as a potential treatment for Long COVID Syndrome (Long COVID), which is now known officially as Post-Acute Sequelae of COVID-19 (PASC2).
- Related: Tonix Pharma To Test Its Fibromyalgia Candidate In Long COVID Syndrome.
- Tonix plans to submit the IND in Q4 of 2021 to support a Phase 2 study in a subset of Long COVID patients whose symptoms overlap with fibromyalgia.
- Also Read: IDMC Recommends Tonix Pharma To Stop Enrollment In Fibromyalgia Trial.
- Related content: Benzinga’s Full FDA Calendar.
- Price Action: TNXP shares are up 16.1% at $0.80 during the premarket session on the last check Tuesday.
Why Upstart Shares Are Getting Hammered Today
Upstart Holdings Inc (NASDAQ: UPST) shares are trading lower by 15.86% at $43.40. Stocks have been highly volatile following the Federal Reserve’s recent 50 basis point rate hike, which has weighed on the Nasdaq heavily.
